|
|
Volumn 75, Issue 5-6, 2011, Pages 573-574
|
|
Functional validation confirms genomic phenotypes of glioblastoma with implications for targeted therapy
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLIN DEPENDENT KINASE INHIBITOR 2A;
MAMMALIAN TARGET OF RAPAMYCIN;
PHOSPHATIDYLINOSITOL 3 KINASE;
PLATELET DERIVED GROWTH FACTOR A;
PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;
PROTEIN KINASE B;
PROTEIN TYROSINE PHOSPHATASE SHP 2;
ASTROCYTE;
CANCER CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CARCINOGENICITY;
CELL PROLIFERATION;
DRUG TARGETING;
ENDOTHELIUM CELL;
FUNCTIONAL GENOMICS;
GENE AMPLIFICATION;
GENE EXPRESSION REGULATION;
GLIA CELL;
GLIOBLASTOMA;
GLIOMA CELL;
HUMAN;
NONHUMAN;
PHENOTYPE;
PROGNOSIS;
PROTEIN EXPRESSION;
PROTEIN INDUCTION;
SHORT SURVEY;
SIGNAL TRANSDUCTION;
SURVIVAL TIME;
TREATMENT RESPONSE;
TUMOR NECROSIS;
TUMOR VASCULARIZATION;
ANIMAL;
BIOSYNTHESIS;
BRAIN TUMOR;
GENETIC MARKER;
GENETICS;
METABOLISM;
METHODOLOGY;
MOLECULARLY TARGETED THERAPY;
MOUSE;
NOTE;
PATHOLOGY;
ANIMALS;
BRAIN NEOPLASMS;
CYCLIN-DEPENDENT KINASE INHIBITOR P16;
GENETIC MARKERS;
GLIOBLASTOMA;
HUMANS;
MICE;
MOLECULAR TARGETED THERAPY;
PHENOTYPE;
RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;
|
|
EID: 80052174200
PISSN: 18788750
EISSN: 18788769
Source Type: Journal
DOI: 10.1016/j.wneu.2011.03.029 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (1)
|
